当前在线人数16704
首页 - 分类讨论区 - 海外生活 - 股海弄潮版 - 同主题阅读文章

此篇文章共收到打赏
0

  • 10
  • 20
  • 50
  • 100
您目前伪币余额:0
未名交友
[更多]
[更多]
What about ZIOP @6.5
[版面:股海弄潮][首篇作者:drugbull] , 2017年10月06日00:04:44 ,132次阅读,0次回复
来APP回复,赚取更多伪币 关注本站公众号:
[分页:1 ]
drugbull
进入未名形象秀
我的博客
[回复] [回信给作者] [本篇全文] [本讨论区] [修改] [删除] [转寄] [转贴] [收藏] [举报] [ 1 ]

发信人: drugbull (赶英超美), 信区: Stock
标  题: What about ZIOP @6.5
发信站: BBS 未名空间站 (Fri Oct  6 00:04:44 2017, 美东)

Anyone is interesting it @6.5 ?

it seems a good entry point.

target 14, but I don't know how long time to wait.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to
develop, acquire and commercialize, on its own or with partners, a portfolio
of cancer therapies that address unmet medical needs. The Company is
focused on developing products in immuno-oncology that employ gene
expression, control and cell technologies to deliver cell- and viral-based
therapies for the treatment of cancer and graft-versus-host-disease. It has
developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-
tumorally under the control of the RheoSwitch Therapeutic System (RTS)
expression platform. Its initial clinical stage product candidate, which is
being developed using the immuno-oncology platform is Ad-RTS-IL-12 +
veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce
interleukin-12. As of December 31, 2016, it had completed two Phase II
studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic
melanoma and metastatic breast cancer.
--
※ 修改:·drugbull 於 Oct  6 00:13:51 2017 修改本文·[FROM: 128.]
※ 来源:·WWW 未名空间站 网址:mitbbs.com 移动:在应用商店搜索未名空间·[FROM: 128.]

 
[分页:1 ]
[快速返回] [ 进入股海弄潮讨论区] [返回顶部]
回复文章
标题:
内 容:

未名交友
将您的链接放在这儿

友情链接


NAI500-北美潜力股搜集站
手續費最划算的美股券商
 

Site Map - Contact Us - Terms and Conditions - Privacy Policy

版权所有,未名空间(mitbbs.com),since 1996